Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
HIV, Herpes Simplex Infections
Interventions
MB66, Placebo Film
Drug
Lead sponsor
KBio Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Completed No phase listed Observational

Longitudinal Study of Vaginal Flora

NCT00340275
Conditions
Vaginal Flora
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
15 Years to 44 Years · Female only
Enrollment
5,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Completed No phase listed Observational Accepts healthy volunteers

Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women

NCT02272231
Conditions
Vaginosis, Bacterial
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

NCT03762772
Conditions
Hiv, HSV
Interventions
TAF/EVG Vaginal Insert
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women

NCT02010593
Conditions
Human Immunodeficiency Virus
Interventions
Dapivirine Vaginal Ring, Placebo Vaginal Ring
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania
Conditions
CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions
Artesunate vaginal insert, Placebo vaginal insert
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
25 Years to 100 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Completed No phase listed Observational Accepts healthy volunteers

Long-Acting Progestin Contraception and the Vaginal Microbiome

NCT02740998
Conditions
Sexually Transmitted Infection
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Conditions
Vaginal Infection
Interventions
Metronidazole, Gel vehicle
Drug
Lead sponsor
Curatek Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 28 more
Conditions
Bacterial Vaginosis
Interventions
BNT331, Placebo
Drug · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Marrero, Louisiana • Metairie, Louisiana + 3 more
Conditions
Recurrent Urinary Tract Infection
Interventions
Estradiol vaginal cream, Estradiol Vaginal Tablet
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis

NCT02185456
Conditions
Bacterial Vaginosis
Interventions
750 mg metronidazole/ 200 mg miconazole vaginal suppository, Standard of care
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Completed No phase listed Observational Accepts healthy volunteers

Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women

NCT03196492
Conditions
Microbial Colonization
Interventions
No intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 24 Years · Female only
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers

Study of UC-781 Vaginal Microbicide

NCT00132444
Conditions
HIV Infections
Interventions
topical vaginal application of UC-781 gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Trichomonas Vaginitis, Bacterial Vaginitis
Interventions
Metronidazole 500 mg, Secnidazole 2000 MG
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
4
States / cities
Birmingham, Alabama • North Miami, Florida • New Orleans, Louisiana
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Comparative Performance of a Vaginal Yeast Test

NCT05079711
Conditions
Vulvovaginal Candidiasis
Interventions
SavvyCheck Vaginal Yeast Test (rapid, point-of-care diagnostic test)
Device
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Fort Bragg, North Carolina • Fort Sam Houston, Texas
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
21
States / cities
Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
Completed No phase listed Observational Results available

Laser Therapy for Treatment of Urogenital Symptoms in Women

NCT03681678
Conditions
Genitourinary System; Disorder, Female, Burning Vagina, Dyspareunia, Irritation; Vagina, Menopause Related Conditions, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Tract Infections, Stress Urinary Incontinence
Interventions
fCO2 Laser Therapy Group
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Royal Oak, Michigan
Completed Phase 4 Interventional Results available

Preventing Recurrent UTI With Vaginal Estrogen

NCT05551949
Conditions
Recurrent Urinary Tract Infection, Urinary Tract Infections, Cystitis Recurrent
Interventions
Vaginal estradiol tablets
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
55 Years to 100 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • San Diego, California • Lake Worth, Florida + 19 more
Completed No phase listed Observational Accepts healthy volunteers

Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis

NCT02143154
Conditions
GBS Positive, Women in Labor Given Vancomycin for Prophylaxis
Interventions
Not listed
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Bacterial Vaginosis
Interventions
Flourish HEC Vaginal Care System
Device
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Conditions
Sexually Transmitted Infections, HIV Infections
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Dapivirine Vaginal Ring (VR) in Adolescents

NCT02028338
Conditions
Human Immunodeficiency Virus
Interventions
placebo ring, dapivirine ring
Combination Product
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
15 Years to 17 Years · Female only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Aurora, Colorado • Boston, Massachusetts + 3 more
Completed Phase 2 Interventional Accepts healthy volunteers

TOL-463 Phase 2 Study for Vaginitis

NCT02866227
Conditions
Bacterial Vaginosis, Vulvovaginal Candidiasis
Interventions
TOL-463
Drug
Lead sponsor
Toltec Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington